These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31310573)

  • 1. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists.
    Adashek ML; Feldman M
    J Oncol Pract; 2019 Sep; 15(9):502-504. PubMed ID: 31310573
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 3. Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid.
    Sindel A; Taylor T; Chesney A; Clark W; Fowler AA; Toor AA
    Eur J Haematol; 2019 Aug; 103(2):134-136. PubMed ID: 31140644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for classical Hodgkin's lymphoma.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
    [No Abstract]   [Full Text] [Related]  

  • 5. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
    Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
    Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
    Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK; Margull J
    Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
    Jang S; Venna S
    J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy.
    Leempoel J; Ruyssen A; Kessler R; Van Pesch V; Gille M
    Acta Neurol Belg; 2020 Apr; 120(2):451-452. PubMed ID: 31264180
    [No Abstract]   [Full Text] [Related]  

  • 10. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 11. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
    Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA; Bilal U; Prasad V
    Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract]   [Full Text] [Related]  

  • 14. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.
    Bender C; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
    Ann Oncol; 2016 Jul; 27(7):1353-4. PubMed ID: 26951629
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.
    Dimitriou F; Matter AV; Mangana J; Urosevic-Maiwald M; Micaletto S; Braun RP; French LE; Dummer R
    J Immunother; 2019 Jan; 42(1):29-32. PubMed ID: 29939877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
    Cousin S; Toulmonde M; Kind M; Cazeau AL; Bechade D; Coindre JM; Italiano A
    Ann Oncol; 2016 Jun; 27(6):1178-1179. PubMed ID: 27091806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.